Ruxolitinib Cream Showed Promise for Skin Graft-Versus-Host Disease
A clinical trial found that ruxolitinib cream significantly improved skin symptoms in patients with chronic graft-versus-host disease.
Updated on Oct. 6, 2026 in Cancer
Live Poll
Do you believe developing topical alternatives to standard steroids is important for chronic disease management?
In research concluded in September 2022, ruxolitinib 1.5% cream reduced affected skin surface areas in patients suffering from cutaneous chronic graft-versus-host disease. The study demonstrated clinical efficacy compared to a placebo vehicle without significant adverse side effects.
Why it matters
Topical corticosteroids, the standard treatment for this condition, are often limited by complications like skin atrophy and infection. This research suggests a potential alternative that avoids these common risks while targeting the skin disease directly.
In the trial of 24 patients, ruxolitinib 1.5% cream was applied twice daily over 28 days. The cohort had a median age of 47.5 years, with 67% of participants having underlying acute leukemia.
The players
Memorial Sloan Kettering Cancer Center
This is a prominent cancer research and treatment institution based in New York, New York, that served as the clinical site for the trial.
The details
Researchers at Memorial Sloan Kettering Cancer Center assigned patients to apply ruxolitinib to one side of their body and a placebo to the other. By day 28, the treatment side showed a clinical response in 74% of evaluable patients with no instances of skin thinning or atrophy reported.
Timeline
Patient enrollment and randomization occurred from June 28, 2019, to September 8, 2022.
Previous topical therapies were discontinued on Day 0 of the study.
Assessments of skin surface area and clinical scores were performed on Day 14.
The primary end point and final treatment assessment occurred on Day 28.
The Big Picture
This study aligns with the broader research efforts at Memorial Sloan Kettering Cancer Center to refine post-transplant care. It represents an incremental step in improving quality of life for transplant survivors by minimizing the side effects associated with legacy corticosteroid treatments.
For patients suffering from chronic graft-versus-host disease, this study offers the prospect of a targeted topical treatment that avoids the skin-thinning risks of steroids. It underscores the potential for future treatment plans that prioritize both efficacy and the preservation of skin health.
The takeaway
This trial highlights a shift toward more specialized topical therapies that can address complex post-transplant conditions without the common side effects of traditional medication. Patients currently managing similar dermatological symptoms should consult their oncology teams about the latest non-steroidal treatment research.
Further reading
Learn more about the latest research and developments in Cancer studies.
Source note: This article includes information reported by OncLive.
Live Poll
Do you believe developing topical alternatives to standard steroids is important for chronic disease management?
